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A b s t r a c t
This study evaluated the diagnostic usefulness of 
tumor marker concentrations in cytologic fluids (CF) 
for subtyping non–small cell lung cancer (NSCLC) 
and assessed the relationship between fluorine-18-
fluorodeoxyglucose (18F-FDG) uptake with serum 
and CF tumor marker levels. This prospective study 
included 88 patients diagnosed with adenocarcinoma 
or squamous cell carcinoma (SCC). Cytokeratin-19 
fragment (CYFRA 21-1), carcinoembryonic antigen 
(CEA), and squamous cell carcinoma antigen (SCCA) 
concentrations in the CF samples were correlated with 
serum tumor marker concentrations, 18F-FDG uptake, 
and NSCLC subtype.
Fifty-eight patients were diagnosed with 
adenocarcinoma. Multivariate analysis revealed higher 
CF and serum SCCA levels; smoking status predicted 
SCC from adenocarcinoma. CF SCCA showed the 
highest accuracy (83%) in distinguishing between SCC 
and adenocarcinoma. CF samples obtained during 
routine needle aspiration biopsy procedure contain 
tumor marker levels sufficient to distinguish between 
SCC and adenocarcinoma; CF SCCA had the highest 
diagnostic accuracy.
Lung cancer, the leading cause of cancer death world-
wide, has a 5-year survival rate of less than 15%. However, 
recently developed chemotherapeutic agents and molecular 
targeting agents for lung cancer have significantly improved 
the prognosis for nonsquamous non–small cell lung cancer 
(NSCLC).1-5 Accordingly, accurate subclassification of these 
NSCLCs becomes increasingly important.
Despite increasing public awareness of lung cancer and 
use of screening tests, fewer than 20% of patients newly 
diagnosed with lung cancer qualify for surgery. Thus, to 
optimize the use of available nonsurgical and palliative treat-
ments, accurate diagnosis and subtyping are of paramount 
importance. The current established biopsy methods include 
computed tomography (CT)– or fluoroscopy-guided trans-
thoracic needle aspiration biopsy (NAB) and transbronchial 
needle aspiration. Although these methods provide satisfac-
tory diagnostic accuracy for malignancy, the reported accu-
racy for NSCLC subtyping varies.6-8 To increase subtyping 
accuracy in NSCLC, methods using serum tumor markers9 
and immunohistochemical staining of biopsy specimens have 
been investigated.10,11
Factors that significantly reduce accuracy of diagnosis 
and subtyping of NSCLC include small sample size and 
tumor heterogeneity. In large necrotic tumors, necrotic debris 
may be aspirated in higher proportion than viable tumor cells. 
The 3 tumor markers most often used clinically are squa-
mous cell carcinoma antigen (SCCA), cytokeratin-19 frag-
ment (CYFRA 21-1), and carcinoembryonic antigen (CEA). 
Because these markers originate in tumor cells, fluids directly 
aspirated from the tumor may contain higher tumor marker 
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concentrations than the serum, and these cytologic fluid (CF) 
markers may reflect tumor histopathology more accurately 
than those of serum tumor markers. We hypothesized that 
analysis of tumor markers in fluid specimens obtained by 
aspiration would increase the accuracy in subtyping NSCLC.
Fluorine-18-fluorodeoxyglucose positron emission 
tomography (18F-FDG PET) is currently well integrated into 
the diagnostic workup for lung cancer. The 18F-FDG uptake 
in the primary lung malignancy correlates positively with 
tumor size,12 glucose transporter-1,13 and Ki-67 index (MIB-1 
staining, proliferation marker)14 and negatively with progno-
sis.15,16 Studies also correlate 18F-FDG uptake with histologic 
grading17 because 18F-FDG uptake is lower in adenocarci-
noma than in squamous cell carcinoma (SCC) and small cell 
carcinoma.18 However, no studies to date have shown the cor-
relation between tumor marker levels with 18F-FDG uptake in 
patients with lung cancer.
We conducted this study to evaluate the diagnostic use-
fulness of CF tumor markers for NSCLC subtyping and to 
assess the relationship between 18F-FDG uptake in the pri-
mary lesion with serum and CF tumor marker levels. 
Materials and Methods
Patient Selection
The 261 patients enrolled in this prospective study 
underwent transthoracic NAB for the differential diagnosis of 
a pulmonary nodule or mass on CT during the interval from 
November 1, 2009, to July 31, 2010. Patients met inclusion 
criteria if they were more than 20 years of age and had a solid 
lesion, which was defined as a lesion greater than 8 mm with 
ground glass opacity component less than 50%. Patients were 
excluded if they had lesions with ground glass opacity (n = 
19) or refused to provide written informed consent (n = 21). 
Of these 221 patients, 148 patients had malignant lesions, 
56 had benign lesions, and 17 had indeterminate results. To 
test the application of CF tumor marker levels in subtyping 
NSCLCs, only patients with lesions pathologically confirmed 
to be adenocarcinoma or SCC were included (9 patients with 
small cell lung cancer or lymphoma, 3 with large cell carci-
noma, 17 with NSCLC of undetermined subtype, and 31 with 
cytologically confirmed NSCLC subtype were excluded). 
Finally, 88 patients (64 men and 24 women; average age, 66.4 
years; range, 39-87 years) who had pathologically confirmed 
adenocarcinoma or SCC were included. All patients under-
went routine 18F-FDG PET/CT within 10 days of biopsy to 
evaluate for distant metastasis before further therapy. The 
patient selection process is summarized in ❚Figure 1❚. 
Data collection was systematized and a standardized 
registration form was prepared. The institutional review board 
approved the study protocol, and all patients provided written 
informed consent.
Percutaneous Transthoracic NAB Technique
The biopsies were performed by 3 chest radiologists who 
had 4, 6, and 10 years of experience performing thoracic biop-
sies. Fluoroscopy-guided biopsy interventions (n = 20) were 
performed using a Medix 130 fluoroscope (Hitachi Medical 
Corporation, Tokyo, Japan), and CT-guided biopsy interven-
tions (n = 68) were performed using a 16-MDCT scanner 
(Somatom Sensation 16, Siemens Medical Solutions, Mal-
vern, PA) equipped with CARE Vision software (Siemens). 
During each procedure, more than 2 aspiration specimens 
were obtained using 20- to 22-gauge Chiba needles connected 
to a 10-mL syringe without additional needle punctures. Part 
of each aspirate was spread onto glass slides and smears pre-
pared for cytologic examination; another part of the material 
was prepared in a tube for cell block processing. All smears 
were immediately placed in 95% ethanol for Papanicolaou 
(Pap) staining. The remainder of each aspirate (1-2 mL) was 
rinsed with 1 mL of normal saline solution in a tube for evalu-
ating cytologic tumor markers.
Tumor Marker Analysis
Blood and CF specimens were collected from each 
patient before beginning any therapy. Serum and CF superna-
tants were obtained by centrifugation at 2,000g for 10 minutes 
Suspected lung cancer
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CT: solid lesions
(n = 261)
NAB with blood and
cytology tumor
marker sampling
(n = 221)
Malignant lesions
(n = 148)
Pathology: ADC, SCC
(n = 88)
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Interdeterminate
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❚Figure 1❚ Overview of the study design. ADC, 
adenocarcinoma; CT, computed tomography; GGO, ground 
glass opacity; NAB, needle aspiration biopsy; NSCLC,  
non–small cell lung cancer; SCC, squamous cell carcinoma. 
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and stored at –40°C before performing tumor marker assays 
using commercial immunoassay kits. Technicians performing 
assays of both CF and serum samples were blinded to the 
corresponding diagnoses. CYFRA 21-1 levels were measured 
using an electrochemiluminescent immunoassay (CYFRA 
21-1, Roche Diagnostics, Mannheim, Germany), CEA levels 
were measured using a chemiluminescence immunoassay 
(Centaur CEA, Bayer HealthCare, Tarrytown, NY), and 
SCCA levels were measured using an immunoradiometric 
assay (SCC-RIABEAD, SRL, Tokyo, Japan). Tumor markers 
in each of the CF samples were evaluated twice, and the mean 
values were used for analysis. Detectable levels for each CF 
tumor marker were defined as follows: 0.1 to 500 for CYFRA 
21-1; 0.1 to 500 for CEA; and 0.01 to 150 for SCCA.
Histologic Analysis
The CF specimen from the NAB was fixed in 95% 
ethanol and stained using the Pap method. The tumor tissue 
sample collected during the operation was imprinted on a 
glass slide. Tissue sections were processed for H&E staining. 
Histologic classification was done according to the proposed 
International Association for the Study of Lung Cancer/
American Thoracic Society/European Respiratory Society 
international multidisciplinary classification of lung adeno-
carcinoma. If there was a disagreement in the histopathologic 
analysis, a consensus was achieved by a joint reading.
PET/CT Protocol
All patients underwent routine 18F-FDG PET/CT scan-
ning with DSTe PET/CT (GE Healthcare, Milwaukee, WI). 
All patients fasted for at least 6 hours, and glucose levels in 
peripheral blood in all patients were confirmed to be 140 mg/
dL (7.8 mmol/L) or less before 18F-FDG injection. Approxi-
mately 5.5 MBq/kg of body weight of 18F-FDG was admin-
istered intravenously 1 hour before image acquisition. After 
the initial low-dose CT, a standard PET imaging scan from 
the neck to the proximal thighs with an acquisition time of 3 
minutes/bed in 3-dimensional mode was performed. 
Imaging Analysis 
One experienced nuclear medicine specialist who was 
blind to the clinical information interpreted the PET images 
qualitatively by visual inspection. Visual analysis was per-
formed at a GE AW 4.0 workstation. Semiquantitative 
analysis was performed by drawing a region of interest on 
the whole lung mass that was aspirated, and the maximum 
standard uptake value (SUV) was obtained.
Statistical Analysis
Differences between the adenocarcinoma and SCC 
groups were evaluated using the Fisher exact test (sex, T 
stage, TNM stage) or t test (CF and blood tumor marker 
levels, SUV, age, tumor size). A paired t test was performed 
to compare each patient’s tumor marker levels in CF with 
those in serum. Correlations between CF and serum tumor 
markers, SUV, age, and tumor size were performed using 
the Pearson correlation analysis. Student t test was used to 
compare CF and serum tumor marker levels and SUV with 
the absence or presence of distant metastases. To predict 
NSCLC subtype, pathology results were used as a reference 
standard. Univariate analysis was performed to evaluate for 
significant correlations in CF and serum tumor marker lev-
els, PET SUV, as well as other clinical data such as patient 
age, tumor size, gender, T stage, and TNM stage. Statisti-
cally significant findings on univariate analysis were used in 
multivariate analysis.
Receiver operating characteristic (ROC) curves were 
constructed using the CF and serum tumor marker values. 
To compare the performance of CF and serum tumor mark-
ers, the areas under the curves (AUCs) were compared using 
the DeLong method for statistical significance.19 A cutoff 
value was determined for the optimal differentiation between 
adenocarcinoma and SCC. The cutoff level selected for each 
marker was based on the best diagnostic accuracy. The accu-
racy of tumor markers was compared using the generalized 
estimating equation method. Statistical analyses were per-
formed with SAS software (version 9.2 for Windows; SAS 
Institute, Cary, NC), and P values less than .05 were consid-
ered statistically significant.
Results
Patient Demographics
Of the 261 patients initially identified, 88 patients (34%) 
had a pathologically confirmed subtype of adenocarcinoma (n 
= 58) or SCC (n = 30) and underwent PET/CT before further 
therapy. Of these 88 patients, 46 had histologic confirmation 
either with a lobectomy (n = 45) or an excisional biopsy (n 
= 1), and the remaining patients had histologic confirmation 
on transbronchial or NAB of the lung. ❚Table 1❚ summa-
rizes characteristics of the patients included in our study. We 
divided the smoking history into former (defined as more than 
3 months of smoking cessation before lung cancer diagnosis), 
current smokers, and never smokers. In accordance with 
previous reports,20,21 a history of never smoking was signifi-
cantly more prevalent among patients with adenocarcinoma 
than among those with SCC. Former and current smokers 
were also subcategorized according to pack-years and smok-
ing cessation history and compared with NSCLC subtype pre-
diction, but this did not achieve statistical significance, more 
likely because of the small number of patients in each group 
(data not shown). The patients with adenocarcinoma included 
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significantly more women, but this was no longer seen after 
adjusting for smoking history. 
Comparison of CF and Serum Tumor Markers
Concentrations of CYFRA 21-1 were significantly high-
er in the CF samples (mean ± SD, 131.2 ± 172.28; range, 
0.95-500.0) than in serum (mean  ± SD, 9.3 ± 32.77; range, 
0.68-288.0; P < .0001). CEA levels were higher in serum 
(mean ± SD, 35.8 ± 95.63; range, 0.7-500.0) compared with 
CF (mean ± SD, 27.8 ± 79.30; range, 0.1-500.0), but the dif-
ferences were not statistically significant (P = .467). SCCA 
concentrations in CF (mean ± SD, 24.0 ± 46.18; range, 
0.07-150.0) were significantly higher than those in serum 
SCCA (mean ± SD, 1.1 ± 1.25; range, 0.1-9.2; P < .001). 
Pearson correlation data for CF tumor markers are shown 
in ❚Table 2❚. 
Elevated serum CEA levels reportedly indicate the pres-
ence of distant metastasis.22,23 Of our 88 patients, 32 showed 
distant metastasis on PET/CT scans. Patients in the stage IV 
group had significantly higher serum CEA levels compared 
with patients in the stage I-III group (mean ± SD, 86.4 ± 
144.60 vs 6.9 ± 18.18; P = .004). SUV for the primary lesion 
was also higher in the stage IV group than in the stage I-III 
group (mean ± SD, 9.6 ± 5.67 vs 7.1 ± 5.26; P = .042). No 
other serum tumor markers or CF tumor markers were signifi-
cantly different between the stage I-III and stage IV groups.
Prediction of NSCLC Subtype 
Analysis of clinical factors and tumor marker levels in 
predicting NSCLC subtype are shown in Table 1. Univari-
ate analysis showed that CF SCCA, serum SCCA, serum 
CEA, SUV, smoking status, and sex predicted SCC over 
adenocarcinoma. The significant factors on univariate 
analysis were used to predict NSCLC subtype in multi-
variate analysis ❚Table 3❚. Several multivariate models were 
constructed to minimize the effects of confounding factors. 
Model 1 evaluated the strength of association between CF 
SCCA and serum CEA in distinguishing between SCC and 
adenocarcinoma. This model showed that the predictive 
value of serum CEA for SCC was lost when CF SCCA was 
considered. Model 2 reveals that both CF SCCA and serum 
SCCA predict SCC from adenocarcinoma. Considering the 
relationship between SUV and tumor size, model 3 was 
used to evaluate whether SUV can predict SCC when tumor 
size is controlled. Model 4 was used to show that, although 
SUV could predict SCC better than it did adenocarcinoma, 
CF SCCA was a stronger predictor of SCC. When we cor-
related smoking status with other clinical and tumor mark-
ers, we found that smoking status independently predicted 
❚Table 1❚
Baseline Patient Characteristics and Analysis of Variables 
Distinguishing Between ADC and SCC
 Mean ± SD Mean ± SD 
Variable ADC (n = 58)  SCC (n=30)  P
Age, y 65.3 ± 10.34 68.5 ± 6.84 .083
Sex (F/M) 23/35 1/29 <.001a
Lesion size, mm 30.1 ± 20.26 32.0 ± 17.00 .664
Smoking status, No. (%)  .011b
   Former 15 (17) 13 (15) 
   Current  10 (11) 10 (11) 
   Never 33 (38) 7 (8) 
Hypertension 21 10 .820
Diabetes mellitus 9 6 .770
Tuberculosis 4 5 .260
Tumor stage   
   T stage (1/2/3/4) 21/16/9/12 14/4/4/8 .458
   Stage (1/2/3/4) 22/5/7/24 15/2/5/8 .491
Tumor marker   
   Serum SCCA 0.9 ± 0.87 1.6± 1.70 .014a
   Serum CYFRA 21-1 11.7 ± 40.10 4.6 ± 5.23 .336
   Serum CEA 52.0 ± 114.70 4.4 ± 4.99 .003a
   CF SCCA 5.8 ± 18.47 59.3 ± 61.45 <.001a
   CF CYFRA 21-1 113.9 ± 158.59 164.6 ± 194.58 .224
   CF CEA 31.8 ± 94.50 20.0 ± 34.93 .512
   SUV 7.0 ± 5.27 9.9 ± 5.59 .024a
ADC, adenocarcinoma; CEA, carcinoembryonic antigen; CF, cytologic fluid; 
CYFRA 21-1, cytokeratin-19 fragment; SCC, squamous cell carcinoma; SCCA, 
squamous cell carcinoma antigen; SD, standard deviation; SUV, standard uptake 
value.
a Statistically significant (P < .05).
b Statistically significant (P < .05) compared with never smokers.
❚Table 2❚
Univariate Analysis of Variables Correlated With Tumor Markers in Cytologic Fluid and Serum
  CF SCCA CF CEA   CF CYFRA 21-1
Variable Pearson Coefficient P Pearson Coefficient P Pearson coefficient P
SUV 0.295 .005a –0.005 .961 0.067 .535
Size 0.008 .942 0.075 .489 0.125 .248
Age 0.045 .677 0.032 .767 –0.056 .601
Serum SCC 0.106 .324 0.033 .757 0.042 .696
Serum CYFRA 21-1 –0.079 .466 –0.021 .846 0.221 .038a
Serum CEA –0.168 .118 0.324 .002a 0.158 .142
CEA, carcinoembryonic antigen; CF, cytologic fluid; CYFRA 21-1, cytokeratin-19 fragment; SCC, squamous cell carcinoma; SCCA, squamous cell carcinoma antigen; SUV, 
standard uptake value.
a Statistically significant (P < .05).
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SCC. We included smoking status in model 5, and this final 
model identified smoking status, serum SCCA, and CF 
SCCA as the strongest predictors of SCC pathology. 
Areas under the ROC curves are compared in ❚Figure 
2❚. The AUC for CF SCCA (0.86) was significantly larger 
than any other CF or serum tumor markers. The highest cut-
off value for each tumor marker was evaluated using ROC 
analysis. ❚Table 4❚ shows the sensitivity, specificity, positive 
and negative predictive values, and accuracy of each CF and 
serum tumor marker in subtyping NSCLC as adenocarcinoma 
or SCC using the cutoff values obtained from ROC analysis. 
Among the tumor markers, CF SCCA showed the highest 
accuracy, which was significantly higher than serum SCCA 
(83% vs 63.6%; P = .005). The accuracy of serum CEA was 
significantly higher than that of CF CEA (55.7% vs 28.2%; 
P = .002). Serum and CF CYFRA 21-1 did not differ signifi-
cantly in accuracy (47.7% vs 48.9%; P = .857). 
❚Table 3❚
Multivariate Analysis Models to Distinguish Between 
Adenocarcinoma and Squamous Cell Carcinoma
 Odds Ratio 95% CI P
Model 1   
   CF SCCA 0.005 0.004-0.007 <.001a
   Serum CEA 0.000 –0.002-0.000 .104
Model 2   
   CF SCCA 0.005 0.004-0.007 <.001a
   Serum SCCA 0.078 0.011-0.144 .023a
Model 3   
   SUV 0.023 0.004-0.042 .042a
   Size –0.001 –0.007-0.004 .644
Model 4   
   CF SCCA 0.005 0.003-0.007 <.001a
   SUV 0.008 –0.008-0.024 .332
Model 5   
   CF SCCA 0.005 0.003-0.007 <.001a
   Serum SCCA 0.077 0.011-0.142 .022a
   SUV 0.007 –0.008-0.023 .348
   Smoking status 0.189 0.011-0.349 .037a
CEA, carcinoembryonic antigen; CF, cytologic fluid; CI, confidence interval; SCCA, 
squamous cell carcinoma antigen; SUV, standard uptake value
a Statistically significant (P < .05).
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C ❚Figure 2❚ Receiver operating characteristic analyses 
comparing serum tumor markers with cytologic fluid (CF) 
tumor markers in distinguishing squamous cell carcinoma 
from adenocarcinoma. A, CYFRA 21-1 (area under the curve 
[AUC] for CF, 0.59; serum, 0.46; P = .166). B, CEA (AUC for 
CF, 0.51; serum, 0.59; P = .201). C, SCCA (AUC for CF, 0.86; 
serum, 0.70; P = .011). P values indicate significance of the 
AUC comparisons. CYFRA 21-1, cytokeratin-19 fragment; 
CEA, carcinoembryonic antigen; SCCA, squamous cell 
carcinoma antigen.
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Discussion
We have shown in this study that the CF specimens 
obtained during routine NAB procedures contain tumor 
markers potentially useful in subtyping NSCLC. Our results 
indicate that high levels of SCCA obtained in CF specimens 
during NAB provide a sensitive and specific marker for SCC 
as distinguished from adenocarcinoma and that CF SCCA 
performs better than other serum tumor markers in this con-
text. The present findings support previous findings that the 
tumor marker levels in CF may facilitate the subtyping, as 
well as diagnosis, of NSCLC.24 
Serum and Cytologic Tumor Marker Correlation
An additional finding in our study was the correlation 
between tumor marker levels in CF and serum specimens. In 
particular, we found that CF specimens acquired during NAB 
contained significantly higher concentrations of CYFRA 
21-1 and SCCA than the corresponding serum samples. The 
CEA levels tended to be higher in serum than in CF, but this 
most likely reflects higher levels of CEA in patients with 
metastases.22,23
The tumor marker concentrations in CF exceeded those 
in serum, but these correlations were  weak or undetectable. 
Although CYFRA 21-1 concentrations were higher in CF 
than in serum CYFRA 21-1, the correlation between these 2 
markers was weak. This suggests that the factors that govern 
CYFRA 21-1 release into the blood do not depend directly 
on CYFRA 21-1 levels in the tumor. In vitro studies show 
that serum CYFRA21-1 may reflect cell necrosis25-27 and that 
caspase 3, a protease involved in apoptosis, plays a role in 
CYFRA 21-1 formation. Thus, serum CYFRA21-1 alone may 
not be sufficient to detect viable tumor cells, especially when 
the tumor is relatively small, with proportionally smaller 
necrotic regions. Previous studies using immunohistochemi-
cal analysis showed that cytokeratin-19, the marker used for 
CYFRA21-1, stained both adenocarcinoma and SCC strongly 
and indiscriminately.28-30 These results and our own support 
the conclusion that CYFRA 21-1 obtained directly from the 
tumor will not predict NSCLC subtype any more accurately 
than serum CYFRA21-1.
We found that CF SCCA levels were 10-fold higher 
than serum SCCA levels but observed no direct correlation 
between SCCA levels in CF and serum. The serine protein-
ase inhibitor SCCA is a cytoplasmic component of normal 
squamous epithelial cells not usually detected in the serum. 
In tumor cells, SCCA resides in the cytosol, and its presence 
in the serum samples of patients with NSCLC may occur 
through passive release from cells.31,32 This may explain the 
lack of correlation between serum and CF SCCA levels. This 
also suggests that direct aspirates of the tumor will contain 
markedly higher levels of SCCA than serum SCCA, which 
may translate into higher sensitivity for SCC diagnosis.
Production of NSCLC Subtype
Our results identified CF SCCA, from among all of the 
CF and serum tumor markers tested, as the one that distin-
guished between adenocarcinoma and squamous cell carci-
noma with the greatest accuracy. The CF SCCA showed com-
parable sensitivity and superior specificity to serum SCCA 
in NSCLC subtyping. Previous reports show that at a cutoff 
value of 2 ng/mL, serum SCCA is very specific (0.95) but 
has low sensitivity (0.32) in distinguishing SCC from benign 
lesions.23,33 Other studies report that serum SCCA is specific 
but not sensitive in differentiating SCC from adenocarcino-
ma.34,35 We used the cutoff values obtained from the ROC 
curve analysis for both serum and CF tumor markers to com-
pare the sensitivity, specificity, and accuracy of these markers 
under the same conditions. Using the ROC-generated cutoff 
value of 0.63 ng/mL, our results showed that serum SCCA 
had higher sensitivity (90%) and lower specificity (50%) for 
distinguishing SCC from adenocarcinoma compared with 
other studies. This may occur because the ROC analysis 
showed an increase in accuracy due to increased sensitivity 
rather than specificity. In contrast, the serum SCCA value 
❚Table 4❚
Sensitivity, Specificity, Positive and Negative Predictive Values, and Accuracy of Markers for NSCLC Subtyping
      Predictive Values
 Sensitivity, No. (%) Specificity, No. (%) Positive, No. (%) Negative, No. (%) Accuracy, No. (%)
Cytologic fluida     
   CYFRA 21-1 (11.25 ng/mL) 27/30 (90.0) 16/58 (27.6) 27/69 (39.1) 16/19 (84.2) 43/88 (48.9)
   CEA (0.27 ng/mL) 23/30 (76.7)  8/58 (13.8) 23/73 (31.5) 8/15 (53.3) 31/88 (35.2)
   SCCA (5.65 ng/mL) 25/30 (83.3) 48/58 (82.8) 25/35 (71.4) 48/53 (90.6) 73/88 (83.0)
Seruma     
   CYFRA 21-1 (6.51 ng/mL) 28/30 (93.3) 14/58 (24.1) 28/72 (38.9) 14/16 (87.5) 42/88 (47.7)
   CEA (8.45 ng/mL) 28/30 (93.3) 21/58 (36.2) 28/65 (43.1) 21/23 (91.3) 49/88 (55.7)
   SCCA (0.63 ng/mL) 27/30 (90.0) 29/58 (50.0) 27/56 (48.2) 29/32 (90.6) 56/88 (63.6)
CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin-19 fragment; NSCLC, non–small cell lung cancer; SCCA, squamous cell carcinoma antigen.
a Values in parentheses indicate the cutoff values obtained from receiver operating characteristic analysis (see text).
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